Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - INNOVUS PHARMACEUTICALS, INC. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): May 10,
2017
INNOVUS PHARMACEUTICALS,
INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-52991
|
90-0814124
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer Identification No.)
|
|
9171 Towne Centre
Drive, Suite 440, San Diego, CA
|
|
92122
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 964-5123
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR
240.13e-4(c))
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR
240.12b-2) ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
In this
report, “Innovus Pharmaceuticals,” “Innovus
Pharma,” “the Company”, “we,”
“us” and “our” refer to Innovus
Pharmaceuticals, Inc., and/or one or more of our wholly-owned
subsidiaries, unless the context otherwise provides. Innovus
Pharma(R) is a registered service mark of Innovus Pharmaceuticals,
Inc.
Item 8.01 – Other Events
On May 16, 2017, the Company issued a press release announcing that
it had entered into an exclusive license and distribution agreement
with Densmore Pharmaceutical International, a company based in
Monaco for the distribution of its Zestra(R) product in France and
Belgium. Pursuant to the Densmore agreement, Densmore shall provide
Innovus with an up-front payment and has minimum annual purchase
requirements for Zestra(R) during the term of the
agreement.
The
full text of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K.
Item 9.01 -- Financial Statements and Exhibits
(d) Exhibits
|
Exhibit Number
|
|
Description
|
|
99.1
|
|
Press release issued May 16,
2017.
|
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
Date: May 16,
2017
|
INNOVUS
PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
Bassam Damaj
Bassam
Damaj.
President
and Chief Executive Officer
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
|
Description
|
|
99.1
|
|
Press release issued May 16,
2017.
|
|
|
|
|